Evidence map›Paper›PMID 37655102›Full record

ArticleFrontiers in oncology2023

Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor-PET/CT.

Maria Ingenerf, Johannes Rübenthaler, Vera Wenter, Mathias Zacherl, Friederike Völter, Michael Winkelmann, Homeira Karim, Regina Schinner, Jens Ricke, Frank Berger and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Maria IngenerfDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Johannes RübenthalerDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Vera WenterEuropean Neuroendocrine Tumor Society (ENETS) Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at at the University Hospital of Munich (GEPNET-KUM), Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Mathias ZacherlEuropean Neuroendocrine Tumor Society (ENETS) Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at at the University Hospital of Munich (GEPNET-KUM), Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Friederike VölterEuropean Neuroendocrine Tumor Society (ENETS) Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at at the University Hospital of Munich (GEPNET-KUM), Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Michael WinkelmannDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Homeira KarimDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Regina SchinnerDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Jens RickeDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Frank BergerDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Christine Schmid-TannwaldDepartment of Radiology, Ludwig-Maximilians-Universität (LMU) University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Ludwig-Maximilians-Universität München · DEEuropean Neuroendocrine Tumor Society · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The aim of this study was to compare the diagnostic performance of different sets of MR sequences in detecting extrahepatic disease of NETs on routine liver magnetic resonance imaging (MRI). Method: One hundred twenty-seven patients with NETs with and without hepatic and extrahepatic metastases who underwent liver MRI and SSTR-PET/CT were retrospectively analyzed. Two radiologists evaluated in consensus in four sessions: (1) non-contrast T1w+T2w (NC), (2) NC+DWI, (3) NC+ contrast-enhanced T1w (CE), and (4) NC+DWI+CE the presence and number of metastases (lymph nodes, bone, peritoneal surface, lung base, and abdominal organ). Sensitivity, specificity, positive, and negative predictive value for detection of metastases were calculated for each session in a patient-based manner; detection and error rates were calculated for lesion-based analysis. Comparison between the MR-sessions and positron emission tomography-computed tomography (PET/CT) was performed with the McNemar test. Results: Regarding all 1,094 lesions detected in PET/CT, NC+DWI, and NC, CE+DWI identified most true-positive lesions 779 (71%) and 775 (71%), respectively. Patient-based analysis revealed significantly higher sensitivity by NC+DWI (85%) than NC and NC+CE ( Conclusion: The combination of NC+DWI showed better sensitivities than the combination of NC+CE. NC+DWI showed similar, sometimes even better sensitivities than NC+CE+DWI, but with lower specificities.

Indexed as

accuracydiagnostic imagingdiffusion magnetic resonance imagingneuroendocrine tumorssensitivity and specificity

Identifiers

PMID37655102
PMCPMC10465364
OpenAlexW4385953061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.